首页 Karyopharm Therapeutics(usKPTI)-基本信息

Karyopharm Therapeutics(usKPTI)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:9.33

最高价:9.56

成交量:490422.0

昨收价:9.44

最低价:9.2

最新价:9.505

行情图标
概要信息

英文名称:Karyopharm Therapeutics


行业:医疗


简介:Karyopharm Therapeutics Inc.是一家专注于研发新式一期核运输癌症治疗方法的临床型制药公司


电话:1-617-6580600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Karyopharm Therapeutics是一家临床阶段的制药公司,总部位于美国马萨诸塞州的牛顿市,专注于新型一流药物的发现,开发和商业化,这些药物主要针对核转运,用于治疗癌症和其他主要疾病。Karyopharm是口服选择性核输出抑制剂(SINE)技术的行业领导者,该技术旨在通过抑制输出,特别是XPO1来解决肿瘤发生的中心机制。Karyopharm的主要候选产品——Selinexor(KPT-330)已在世界范围内进行血液系统恶性肿瘤或实体瘤患者的临床试验治疗。Selinexor目前处于: 治疗难治性多发性骨髓瘤的 IIb 期临床研究阶段; 结合骨髓治疗治疗多发性骨髓瘤的 Ib/II 期临床研究阶段; 结合Velcade(硼替佐米)和地塞米松治疗多发性骨髓瘤的 III 期临床试验阶段; 治疗弥漫性大B细胞淋巴瘤的 IIb 期临床研究阶段; 治疗脂肪肉瘤的II / III期临床研究阶段; 治疗子宫内膜癌的 III 期临床试验阶段; 治疗多形性胶质母细胞瘤的 II 期临床试验阶段。Karyopharm目前正准备在2019年首次在美国进行Selinexor的商业发布。除了selinexor之外,Karyopharm还推出了一系列新型口服候选药物,包括: Eltanexor(KPT-8602),治疗骨髓增生异常综合征,结肠直肠癌和去势抵抗性前列腺癌;处于治疗复发/难治性多发性骨髓瘤的 I/II 期临床试验阶段。 Verdinexor(KPT-335),作为抗病毒药物,作为伴侣动物癌症的潜在的治疗方法,目前处于 IIb 期临床试验阶段; KPT-9274,一种双重PAK4 / NAMPT抑制剂,用于治疗晚期实体恶性肿瘤或非霍奇金淋巴瘤,目前处于 I 期临床试验阶段; KPT-350,处于临床前阶段,用于治疗神经系统疾病,炎症和自身免疫性疾病。

交易日期 交易人 职位 类型 交易份额 价格
2016-11-13 Frenkel (Ran) Officer Sell 3309 10.06
2016-11-08 Primiano Christopher Brett General Counsel Sell 4342 8.19
2016-11-08 Renz (Justin A) Chief Financial Officer Sell 4342 8.19
2016-11-04 Frenkel (Ran) Officer Buy 15000 --
2016-11-04 Primiano Christopher Brett General Counsel Buy 15000 --
2016-11-04 Renz (Justin A) Chief Financial Officer Buy 15000 --
2016-06-22 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 18824 8.03
2016-06-12 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 7074 8.51
2016-06-08 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 30000 9.14
2016-06-07 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 15541 9.34
2016-06-06 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 20000 9.25
2016-06-05 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 20000 9.22
2016-06-01 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 17855 9.65
2016-05-31 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 17568 9.64
2016-05-30 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 17096 9.66
2016-05-26 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 40000 9.58
2016-05-25 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 18182 9.59
2016-05-24 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 27940 9.83
2016-05-22 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 33932 8.77
2016-05-19 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 40000 8.52
2016-05-18 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 20000 8.18
2016-05-17 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 30000 8.15
2016-05-16 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 33800 8.15
2016-05-15 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 10000 8.01
2016-05-12 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 400 8.01
2016-05-10 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 11868 8.41
2016-05-09 Chione, Ltd. Beneficial Owner of More than 10% Class Sell 20000 8.14
2015-12-29 Kauffman (Michael G) Chief Executive Officer Gift 3144 --
2015-12-29 Shacham (Sharon) President Gift 3144 --
2015-12-29 Kauffman (Michael G) Chief Executive Officer Gift 3144 --
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments Inc 963864 1.58% 11740 1.23% 2019-07-31
Candriam Luxembourg S.C.A. 1866778 3.07% 74234 4.14% 2019-03-31
BlackRock Fund Advisors 2608741 4.29% -33309 -1.26% 2019-07-31
Vanguard Group Inc 2614272 4.30% 885385 51.21% 2019-03-31
Millennium Management LLC 2719714 4.47% 2272107 507.61% 2019-03-31
BlackRock Inc 4178808 6.87% -79104 -1.86% 2019-03-31
Consonance Capital Management LP 5158884 8.48% 348806 7.25% 2019-03-31
Palo Alto Investors, LLC 5262263 8.65% 576911 12.31% 2019-03-31
Wellington Management Company LLP 8437359 13.86% 220578 2.68% 2019-03-31
Candriam Belgium 1815500 2.98% -- -- 2019-07-31
Citadel Advisors Llc 1792404 2.94% 1540334 611.07% 2019-03-31
Vanguard Investments Australia Ltd 1761143 2.89% -62 -- 2019-07-31
Fidelity Management and Research Company 1533800 2.52% -341340 -18.20% 2019-03-31
FMR Inc 1533800 2.52% -341340 -18.20% 2019-03-31
Emerald Advisers, LLC 1508094 2.48% 51621 3.54% 2019-03-31
Emerald Mutual Fund Advisers Trust 1376475 2.26% 3038 0.22% 2019-03-31
Dimensional Fund Advisors, Inc. 1129958 1.86% 456184 67.71% 2019-03-31
Hartford Funds Management Company, LLC 1120133 1.84% -- -- 2019-07-31
Fidelity SelectCo, LLC 1066743 1.75% -251540 -19.08% 2019-07-31
Dimensional Fund Advisors LP 965912 1.59% 4376 0.46% 2019-07-31
State Street Corporation 963678 1.58% -1559697 -61.81% 2019-03-31
Ridgeback Capital Investments L.p. 3945200 6.48% 3945200 -- 2018-12-31
BlackRock Asset Management Canada Ltd 1216848 2.00% 411 0.03% 2019-05-31
Candriam Luxembourg 1866778 3.07% 74234 4.14% 2019-03-31
Geode Capital Management, LLC 1115854 1.83% 584285 109.92% 2018-12-31
Point72 Asset Management, L.P. 1541718 2.53% 691225 81.27% 2018-12-31
Franklin Advisers, Inc. 1784696 2.93% -40317 -2.21% 2018-12-31
Franklin Resources Inc 1799696 2.96% -40317 -2.19% 2018-12-31
SSGA Funds Management Inc 1603426 2.63% -9362 -0.58% 2019-02-28
TIAA-CREF Investment Management LLC 1042116 1.72% 471117 82.51% 2018-09-30
BlackRock Institutional Trust Company NA 1330245 2.19% 503105 60.82% 2018-06-30
Northern Trust Corp 601974 0.99% 204680 51.52% 2018-06-30
Two Sigma Investments LLC 504809 0.83% 382921 314.16% 2018-06-30
Emerald Advisers Inc 561317 0.93% 561317 -- 2018-06-30
Northern Trust Investments N A 601228 0.99% 203934 51.33% 2018-06-30
Franklin Advisers Inc 2082756 3.44% 51272 2.52% 2018-06-30
State Street Corp 2337707 3.86% 1348776 136.39% 2018-06-30
Chione Ltd. 8549920 17.26% -- -- 2017-12-31
Private Capital Advisors, Inc. 416900 0.69% 416900 -- 2018-06-30
Schonfeld Strategic Advisors LLC 415600 0.69% 52708 14.52% 2018-06-30
Delaware Management Business Trust 338000 0.56% 338000 -- 2018-06-30
Teachers Advisors Inc 332678 0.55% -101759 -23.42% 2018-06-30
Delaware Management Company 338000 0.56% -- -- 2018-06-30
Frontier Capital Management CO Inc 307035 0.51% 307035 -- 2018-06-30
venBio Select Advisor LLC 560658 1.13% 560658 -- 2018-03-31
Delphi Management Partners VIII, LLC 2263006 4.80% -- -- 2017-04-28
Iguana Healthcare Management, LLC 300000 0.61% -100000 -25.00% 2017-12-31
J.P. Morgan Investment Management Inc 292000 0.59% -15200 -4.95% 2017-12-31
Baker Bros Advisors LP 216990 0.44% -- -- 2017-12-31
Tekla Capital Management LLC 756679 1.60% -- -- 2017-09-30
TFS Capital LLC 146819 0.37% 130066 776.37% 2016-10-31
BlackRock Advisors LLC 101972 0.26% 1907 1.91% 2016-09-30
Mutual Of America Capital Management LLC 87030 0.21% -436 -0.50% 2016-12-31
J. P. Morgan Chase Bank NA 82400 0.21% -479 -0.58% 2016-09-30
Rhumbline Advisers 81580 0.21% 17120 26.56% 2016-09-30
Deutsche Asset Mgmt Invst Gesenschaft 78430 0.20% 274 0.35% 2016-09-30
Sharon Shacham, Ph.D., M.B.A. 2047662 2.00% 55819266 0.10% 1999-11-30
Michael G. Kauffman, M.D., Ph.D. 2047662 2.00% 55819266 0.10% 1999-11-30
Deepika R. Pakianathan, Ph.D. 2271524 2.00% 61921744 0.10% 1999-11-30
Entities Affiliated with Franklin Resources, Inc. 4652759 2.00% 126834210 0.10% 1999-11-30
Entities Affiliated with FMR LLC 4905084 2.00% 133712590 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Russell 2000 Growth ETF 534232 0.88% 10726 2.05% 2019-07-30
Vanguard Total Stock Market Index Fund 1750506 2.88% -- -- 2019-06-30
iShares Russell 2000 ETF 1260009 2.07% 2464 0.20% 2019-07-30
Wellington Global Health Care Equity 879921 1.45% 1010 0.11% 2019-03-31
Emerald Growth Fund 833486 1.37% -- -- 2019-06-30
Vanguard Extended Market Index Fund 710246 1.17% 3092 0.44% 2019-06-30
iShares Nasdaq Biotechnology ETF 601261 0.99% 6474 1.09% 2019-07-30
Pru Ret Small Cap Growth/Emerald SP 188031 0.31% -- -- 2019-06-30
Hartford Healthcare Fund 457189 0.75% -- -- 2019-06-30
DFA US Small Cap Portfolio 446991 0.73% -- -- 2019-05-31
Delaware Healthcare Fund 380000 0.62% -- -- 2019-06-30
Principal SmallCap Growth Fund I 276139 0.45% 755 0.27% 2019-06-30
AST Small-Cap Growth Portfolio 267472 0.44% -- -- 2019-06-30
Mutual of America Small Cap Growth Fund 209029 0.34% 83415 66.41% 2019-03-31
State Street Russell Small Cap 199195 0.33% -- -- 2019-06-30
Fidelity 193526 0.32% 21133 12.26% 2019-04-30
State Street Russell Small/Mid Cap 192581 0.32% -- -- 2019-06-30
Candriam Eqs L Biotechnology 1815500 2.98% -- -- 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 194516 0.32% 7737 4.14% 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 1015500 1.67% -1701 -0.17% 2019-05-30
TIAA-CREF Quant Small-Cap Equity Fund 249204 0.41% -2800 -1.11% 2019-03-31
NT R2000 Index Fund - NL 187430 0.31% 7336 4.07% 2019-03-31
CREF Stock Account 200051 0.33% -66840 -25.04% 2019-02-28
Hartford Small Company HLS Fund 181083 0.30% -- -- 2019-02-28
Franklin Biotechnology Discovery Fund 463154 0.76% -- -- 2019-01-31
Franklin Small Cap Growth Fund 547757 0.90% -- -- 2019-01-31
Wellington Global Healthcare Equity Fund 878911 1.44% -22150 -2.46% 2018-12-31
SPDR 1558898 2.56% -9522 -0.61% 2019-02-28
Hartford Small Company Fund 155735 0.26% -- -- 2019-01-31
Fidelity Advisor 197640 0.33% -- -- 2018-11-30
Federated MDT Small Cap Core Fund 150389 0.25% 150389 -- 2018-09-30
JHancock Seaport Long/Short Fund 157980 0.26% -- -- 2018-09-30
Tekla World Healthcare Fund 200324 0.33% -- -- 2017-09-30
TEKLA HEALTHCARE OPPORTUNITIES FUND 300000 0.49% -- -- 2017-09-30
JHancock Seaport A 157980 0.26% 12000 8.22% 2018-07-31
Schwab US Small-Cap ETF 137081 0.20% -- -- 2018-09-13
Hartford Small Company A 143313 0.24% -- -- 2018-07-31
iShares Micro-Cap 130073 0.19% -- -- 2018-09-12
iShares Nasdaq Biotechnology 683365 1.00% -1302 -0.19% 2018-09-12
Hartford Small Company HLS IA 174397 0.29% -1200 -0.68% 2018-07-31
TIAA-CREF Small-Cap Equity Instl 236100 0.39% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 1386857 2.29% -- -- 2018-07-31
Franklin Small Cap Growth A 767086 1.27% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 658370 1.09% 5500 0.84% 2018-07-31
CREF Stock R1 517357 0.86% -30010 -5.48% 2018-07-31
Hartford Healthcare A 470304 0.78% -- -- 2018-07-31
Franklin Biotechnology Discovery A 463154 0.77% -- -- 2018-07-31
iShares Russell 2000 Growth 423188 0.62% -408 -0.10% 2018-09-12
Delaware Healthcare A 338000 0.56% -- -- 2018-07-31
Emerald Growth A 287711 0.48% -- -- 2018-07-31
Fidelity Spartan 243073 0.40% -- -- 2018-07-31
JHVIT Small Cap Growth NAV 128743 0.21% 85743 199.40% 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 119093 0.20% 33213 38.67% 2018-06-30
Mutual of America Small Cap Growth 144012 0.29% -- -- 2018-03-31
USAA Science & Technology 104870 0.17% 23200 28.41% 2018-05-31
Hartford Healthcare HLS IA 102878 0.17% 23000 28.79% 2018-05-31
Vanguard Health Care ETF 101416 0.17% 24954 32.64% 2018-05-31
iShares Russell 2000 Value 312819 0.53% -516 -0.16% 2018-06-21
Principal SmallCap Growth I Instl 92181 0.15% 91160 8928.50% 2018-05-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 86396 0.14% 14000 19.34% 2018-05-31
Met Invt Ser WMC Large Cap Rsrch A 91751 0.18% -- -- 2018-03-31
BioShares 83135 0.13% -- -- 2018-06-08
AST Small Cap Value 83100 0.17% -27400 -24.80% 2018-03-31
NVIT Multi-Manager Small Cap Val IV 81700 0.16% -2300 -2.74% 2018-02-28
Tekla Life Sciences Investors 256355 0.54% -- -- 2017-09-30
State Street Russell Small/Mid Cap Idx Fd Cl I 99039 0.21% 2373 2.45% 2017-06-30
DFA US Small Cap I 73020 0.15% -- -- 2017-11-30
JPMorgan US Small Company Instl 157100 0.38% 3900 2.55% 2016-12-31
TFS Market Neutral 133088 0.34% 116335 694.41% 2016-10-31
Fidelity Advisor® Biotechnology Fund 1155857 3.20% -- -- 2015-10-31
Franklin Biotechnology Discovery 1052068 3.00% -- -- 2015-07-31
Franklin US Opportunities 920493 2.60% -3835 -0.40% 2015-06-30
Fidelity® OTC Portfolio 619300 1.70% -- -- 2015-10-31
Pictet-Biotech 399571 1.40% -53571 -11.80% 2014-09-30
iShares Russell 2000 (AU) 380494 1.50% -234 -0.10% 2015-11-27
Franklin Growth Opportunities Fund 223481 0.60% -- -- 2015-09-30
Franklin Small-Mid Cap Growth Fund 219300 0.60% -21000 -8.70% 2015-09-30
Fidelity® Select Biotechnology Portfolio 3571115 10.00% -- -- 2015-10-31
Cambridge Global Equity Corporate Class 200000 0.60% -- -- 2015-03-31

Garen G. Bohlin Garen G. Bohlin is on the board of Proteon Therapeutics, Inc., Collegium Pharmaceutical, Inc., Tetraphase Pharmaceuticals, Inc. and Karyopharm Therapeutics, Inc. In his past career Mr. Bohlin occupied the position of Chairman at SpringLeaf Therapeutics, Inc., Partner at Arthur Andersen LLP, Executive Vice President of Constellation Pharmaceuticals, Inc., President & Chief Executive Officer at Bioverativ Therapeutics, Inc., Chief Operating Officer of Sirtris Pharmaceuticals, Inc. and Executive Vice President for Genetics Institute LLC. He received an undergraduate degree from the University of Illinois.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Barry E. Greene Barry E. Greene is President of Alnylam Pharmaceuticals, Inc. He is also on the board of Acorda Therapeutics, Inc. and Karyopharm Therapeutics, Inc. and Chief Medical Officer at Vicarious Surgical, Inc. In his past career he was Partner at Andersen Consulting LLP (GB), Vice President-Marketing & Customer Services at AstraZeneca Plc and Vice President-Strategic Integration at AstraZeneca Pharmaceuticals LP (a subsidiary of AstraZeneca Plc), General Manager-Oncology Division at Takeda Oncology Co., Chief Business Officer & Executive Vice President at Mediconsult.com, Inc. and Partner at Accenture Ltd. Barry E. Greene received an undergraduate degree from the University of Pittsburgh.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Tanya N. Lewis Currently, Tanya N. Lewis is Senior Vice President-Regulatory Affairs at Karyopharm Therapeutics, Inc. In her past career she held the position of VP-Regulatory Affairs & Quality Assurance at Vion Pharmaceuticals, Inc., VP-Regulatory Affairs & Quality Assurance at Idera Pharmaceuticals, Inc., VP-Regulatory Affairs & Quality Assurance at Seaside Therapeutics, Inc., VP-Regulatory Affairs & Quality Assurance at TESARO, Inc. and Senior Director-Regulatory Affairs at Takeda Oncology Co. Tanya N. Lewis received a graduate degree from Massachusetts College of Art & Design and an undergraduate degree from Northeastern University.
J. Scott Garland Currently, J. Scott Garland occupies the position of President, Chief Executive Officer & Director at Portola Pharmaceuticals, Inc. He is also on the board of Karyopharm Therapeutics, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP for Exelixis, Inc., Head-Sales & Marketing Division at Amgen, Inc., President for Relypsa, Inc. and Vice President-Avastin Franchise at Genentech, Inc. He received an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Fuqua School of Business.
Christopher B. Primiano Christopher B. Primiano holds the position of Secretary, Chief Business Officer & EVP at Karyopharm Therapeutics, Inc. In the past he was Secretary & General Counsel of GlassHouse Technologies, Inc. and Legal Counsel at Wilmer Cutler Pickering Hale & Dorr LLP. He received an undergraduate degree from Georgetown University, a graduate degree from Boston College Law School and an MBA from Wallace E Carroll School of Management.
Michael G. Kauffman Michael G. Kauffman founded Karyopharm Therapeutics, Inc. He is Chief Executive Officer & Director at this company. He is also on the board of Infinity Pharmaceuticals, Inc., Verastem, Inc. and Kezar Life Sciences, Inc. In his past career he was President & Chief Executive Officer for EPIX Pharmaceuticals, Inc. and President & Chief Executive Officer at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.), Medical Director of Biogen, Inc., Science Advisor at Deer Management Co. LLC and Operating Partner at Bessemer Venture Partners LP (a subsidiary of Deer Management Co. LLC), Chief Medical Officer for Onyx Pharmaceuticals, Inc., Chief Medical Officer for Proteolix, Inc., Vice President-Medicine at Takeda Oncology Co. and Executive Vice President-Distribution Operations at The Jones Group, Inc. Dr. Kauffman received an undergraduate degree from Amherst College and a doctorate from The Johns Hopkins University School of Medicine.
Deepa R. Pakianathan Dr. Deepa R. Pakianathan is an Independent Non-Executive Director at Mereo BioPharma Group Plc, an Independent Director at Alder Biopharmaceuticals, Inc., an Independent Director at Karyopharm Therapeutics, Inc., an Independent Director at Calithera Biosciences, Inc., a General Partner at Delphi Ventures, Inc., a Managing Member at Delphi Management Partners VII LLC, a Managing Member at Delphi Management Partners VIII LLC and a Managing Member at Delphi Ventures III LP. She is on the Board of Directors at Mereo BioPharma Group Plc, Alder Biopharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Calithera Biosciences, Inc., National Venture Capital Association and San Francisco Conservatory of Music. Dr. Pakianathan was previously employed as an Independent Director by OncoMed Pharmaceuticals, Inc., an Independent Director by Alexza Pharmaceuticals, Inc., a Senior Biotechnology Banker by J.P. Morgan Partners LLC, a Research Analyst by Genesis Merchant Group Securities LLC, a Vice President by J.P. Morgan & Co. Ltd., and a Postdoctoral Scientist by Genentech, Inc. She also served on the board at PTC Therapeutics, Inc., NeurAxon, Inc., Relypsa, Inc., Phenomix Corp., Adiana, Inc., Antipodean Pharmaceuticals, Inc., Ilypsa, Inc. and Proteolix, Inc. She received her undergraduate degree from the University of Mumbai, a graduate degree from the Advanced Centre for Treatment Research & Education in Cancer, a graduate degree from Wake Forest University and a doctorate degree from Wake Forest University.
Michael G. Kauffman Michael G. Kauffman founded Karyopharm Therapeutics, Inc. He is Chief Executive Officer & Director at this company. He is also on the board of Infinity Pharmaceuticals, Inc., Verastem, Inc. and Kezar Life Sciences, Inc. In his past career he was President & Chief Executive Officer for EPIX Pharmaceuticals, Inc. and President & Chief Executive Officer at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.), Medical Director of Biogen, Inc., Science Advisor at Deer Management Co. LLC and Operating Partner at Bessemer Venture Partners LP (a subsidiary of Deer Management Co. LLC), Chief Medical Officer for Onyx Pharmaceuticals, Inc., Chief Medical Officer for Proteolix, Inc., Vice President-Medicine at Takeda Oncology Co. and Executive Vice President-Distribution Operations at The Jones Group, Inc. Dr. Kauffman received an undergraduate degree from Amherst College and a doctorate from The Johns Hopkins University School of Medicine.
Sharon Shacham Founder of Karyopharm Therapeutics, Inc. and Predix Pharmaceuticals, Inc., Sharon Shacham currently is President & Chief Scientific Officer at Karyopharm Therapeutics, Inc. She previously was Senior Vice President-Drug Development at EPIX Pharmaceuticals, Inc. and Director-Algorithm & Software Development at Predix Pharmaceuticals, Inc. (a subsidiary of EPIX Pharmaceuticals, Inc.). Dr. Shacham received an undergraduate degree, a doctorate and an MBA from Tel-Aviv University.
Cameron Peters Cameron Peters is Vice President-Finance & Assistant Treasurer at Karyopharm Therapeutics, Inc. Mr. Peters previously held the position of Chief Financial Officer at 24M Technologies, Inc., Senior Consultant at Strategic Decisions Group, Vice President-Finance of Luminus Devices, Inc. and Director-Financial Planning at Takeda Oncology Co. He received a graduate degree from Stanford University, an MBA from Stanford Graduate School of Business and an undergraduate degree from Edmund A. Walsh School of Foreign Service.
Michael P. Mason Currently, Michael P. Mason occupies the position of Treasurer, Chief Financial & Accounting Officer of Karyopharm Therapeutics, Inc. In the past Mr. Mason held the position of Treasurer & Vice President-Finance at Alnylam Pharmaceuticals, Inc., Chairman of Invesco Perpetual Select Trust Plc, Principal at KPMG LLP and Controller at Praecis Pharmaceuticals, Inc. He received an MBA from Babson College and an undergraduate degree from Stetson University.
Mikael Dolsten Mikael Dolsten is on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Chief Scientific Officer for Pfizer Inc., Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In his past career he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President of Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC and Senior Vice President at Wyeth Corp. He received a doctorate from the University of Lund.
Ian Karp Presently, Ian Karp occupies the position of Vice President-Investor & Public Relations at Karyopharm Therapeutics, Inc. In the past Mr. Karp held the position of Senior Director-Global Marketing at Medimmune, Inc. and Head-Investor Relations of Shire Plc. Mr. Karp received an undergraduate degree from Emory University and an MBA from Rutgers Business School.
Mansoor Raza Mirza Mansoor Raza Mirza is President-Elect & Executive Director at Nordic Society of Gynecologic Oncology, Chief Oncologist-Oncology Department at Copenhagen University Hospital, Member of The Gynecologic Oncology Group, Member of International Gynecologic Cancer Society, Member of European Society of Gynaecological Oncology, Member of European Society For Radiotherapy & Oncolog, Founding Executive Member at European Network of Gynecologic Oncology Trials Group and Member of American Society of Clinical Oncology and on the board of 5 other companies. Dr. Mirza received a graduate degree from the University of Southern Denmark and a doctorate from Russian State Medical University.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Brian Austad Brian Austad is SVP-Pharmaceutical Sciences & Vendor Management at Karyopharm Therapeutics, Inc. In his past career he held the position of Director-Process Chemistry at Infinity Pharmaceuticals, Inc. and Scientist & Project Manager at Eisai Research Institute of Boston, Inc. He received a doctorate from the University of Wisconsin and an undergraduate degree from the University of Wisconsin-Eau Claire.
Kevin P. Malobisky Presently, Kevin P. Malobisky occupies the position of Senior Vice President-Regulatory Affairs & Quality at Karyopharm Therapeutics, Inc. In his past career Dr. Malobisky was Global Head-Regulatory at Zafgen, Inc. Dr. Malobisky received a graduate degree from Temple University School of Pharmacy, a doctorate from Capella University and an undergraduate degree from The Pennsylvania State University.
Joan Wood Joan Wood holds the position of Chief Human Resources Officer for Karyopharm Therapeutics, Inc. In her past career Ms. Wood was Vice President & Head-Human Resources at Sarepta Therapeutics, Inc. and Senior Vice President-Human Resources at Genzyme Corp. She received an undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Joan Wood Joan Wood holds the position of Chief Human Resources Officer for Karyopharm Therapeutics, Inc. In her past career Ms. Wood was Vice President & Head-Human Resources at Sarepta Therapeutics, Inc. and Senior Vice President-Human Resources at Genzyme Corp. She received an undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University.
Ran Frenkel Ran Frenkel founded Pfc Pharma Focus Israel Ltd. Mr. Frenkel is Chief Development Operations Officer at Karyopharm Therapeutics, Inc. and Vice President-Business Development of 2P2D Solutions Ltd. Mr. Frenkel previously occupied the position of Chief Executive Officer at Pfc Pharma Focus Israel Ltd., Managing Director-EMEA at Clinipace, Inc. and Managing Director at Actelion Pharmaceuticals US, Inc. He received an undergraduate degree from The Hebrew University of Jerusalem.
Ian Karp Presently, Ian Karp occupies the position of Vice President-Investor & Public Relations at Karyopharm Therapeutics, Inc. In the past Mr. Karp held the position of Senior Director-Global Marketing at Medimmune, Inc. and Head-Investor Relations of Shire Plc. Mr. Karp received an undergraduate degree from Emory University and an MBA from Rutgers Business School.
Jatin Shah Dr. Jatin Shah, MD, is a Chief Medical Officer & Executive Vice President at Karyopharm Therapeutics, Inc. He received his undergraduate degree from The Ohio State University, an undergraduate degree from The Ohio State University College of Medicine and a doctorate degree from The Ohio State University.
Perry Monaco Currently, Perry Monaco occupies the position of Senior Vice President-Sales for Karyopharm Therapeutics, Inc.
Ronit Milstein Ms. Ronit Milstein is a Vice President-Operations at Karyopharm Therapeutics, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐